Debenzergoline
| Clinical data | |
|---|---|
| Other names | Propyldebenzergoline |
| Drug class | Dopamine receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C14H22N2 |
| Molar mass | 218.344 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Debenzergoline, or propyldebenzergoline, is a dopamine receptor agonist and partial ergoline.[1][2] It is an analogue of ergoline in which the A ring of the ergoline ring system has been removed.[1][2] The drug strongly inhibits prolactin secretion and produces antiparkinsonian effects in rodents.[1][2] Debenzergoline was first described in the scientific literature by 1980.[1][2]
See also
References
- ^ a b c d Hjorth S, Carlsson A, Lindberg P, Sanchez D, Wikström H, Arvidsson LE, et al. (1982). "8-hydroxy-2-(di-n-propylamino)tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT-receptor stimulating activity". Journal of Neural Transmission. 55 (3): 169–188. doi:10.1007/BF01276574. ISSN 0300-9564. Retrieved 10 February 2026.
The original suggestion by Nichols (1976), that the pyrroleethylamine moiety of the ergots confers dopaminergic properties to drugs of this class was recently experimentally substantiated by Bach et al. (1980), showing that "debenzergoline" (Fig. 4; 6) is a potent dopaminergic stimulant which appears to lack the 5-HT agonistic (or antagonistic) effects seen with many of the ergot derivatives. [...] Fig. 4. Chemical structures of 5-HT (1), 8-OH-DPAT (2), lisuride (3a), LSD (3b), 4-(2-[di-n-propylamino]ethyl)indole (DPAI; 4), 10-OH-octahydrobenzo(f)quinoline (5) and "debenzergoline" (6).
- ^ a b c d Bach NJ, Kornfeld EC, Jones ND, Chaney MO, Dorman DE, Paschal JW, et al. (May 1980). "Bicyclic and tricyclic ergoline partial structures. Rigid 3-(2-aminoethyl)pyrroles and 3- and 4-(2-aminoethyl)pyrazoles as dopamine agonists". Journal of Medicinal Chemistry. 23 (5): 481–491. doi:10.1021/jm00179a003. PMID 7189782.